Checkpoint Therapeutics has commenced the dose expansion portion of its Phase I trial analysing the safety and tolerability of ascending doses of CK-301 in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers.

The trial will evaluate the fixed CK-301 dose of 800mg, the highest amount tested in dose escalation. This will be given every two weeks in up to 40 checkpoint therapy-naïve patients with select tumour types associated with high clinical response rates to anti-PD-1/L1 monotherapies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“The completion of the dose escalation portion of our Phase I trial marks an important milestone in the clinical development of CK-301.”

It seeks to enrol first-line non-small cell lung cancer patients whose tumours have high PD-L1 expression.

The dose expansion study follows the successful completion of the dose escalation portion of the first-in-human, open-label, multi-centre trial.

The trial is currently enroling patients at various sites across Australia, New Zealand and Thailand.

Its secondary endpoints feature the evaluation or characterisation of the pharmacokinetics, immunogenicity and preliminary efficacy of CK-301.

After the dose escalation phase, up to four dose expansion cohorts may be enrolled in the study to further characterise the safety and efficacy of CK-301 in specific patient subgroups.

Checkpoint Therapeutics president and CEO James Oliviero said: “The completion of the dose escalation portion of our Phase I trial marks an important milestone in the clinical development of our anti-PD-L1 antibody, CK-301.

“Our focus now shifts to generating efficacy data in the dose expansion portion of the trial through the enrolment of patients with tumour types believed to have a high potential for objective response to anti-PD-L1 monotherapy.”

Checkpoint plans to report initial data from the new expansion cohort in the second half of this year, and aims to begin the first registration trial of CK-301 for the treatment of first-line non-small cell lung cancer by the first quarter of next year.